Why Is NEWAMSTERDAM PHARMA (NAMS) Stock Down Today?

NAMS stock fell 11.16% to $22.77 in a volatile session driven by heavy selling pressure and uncertainty surrounding its key clinical trials. The stock opened lower, gapped down from the previous close, and continued to decline throughout the day. Institutional options activity and recent earnings results have heightened investor caution.

What Happened

NewAmsterdam Pharma’s stock opened at $25.20, down 1.7% from the prior close, and continued to fall throughout the session. By the close, it had dropped to $22.77, with a low of $22.72 reached at 3:25 PM ET. The decline followed a recent earnings report that showed a Q2 loss of $0.52 per share, missing estimates, and a $3.701M revenue beat. Despite Stifel reiterating a Buy rating after a trial failure and options activity suggesting institutional positioning ahead of the PREVAIL trial results, the stock has struggled with uncertainty. Recent insider transactions also added to the bearish sentiment, with three sales totaling $7.8M reported in the last 90 days.

What The Data Shows

The stock has traded between $23.05 and $42.20 over the past 52 weeks and has printed 55 fresh 52-week lows on September 9. Intraday volume of 0.9 million shares is 0.8 times the 3-month average, indicating moderate participation. The company remains unprofitable with a TTM EPS of -2.14 and a TTM revenue decline of 88.9%. Its low beta of 0.09 suggests minimal correlation with broader market movements.

What To Watch

The stock is approaching a key support level near its 52-week low. Investors should monitor the upcoming PREVAIL trial results and any further updates from analysts, as well as coverage breadth in the coming days.